
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp is advancing its vaccine portfolio, particularly with its shingles vaccine candidate, which has demonstrated vaccine response rates comparable to Shingrix while exhibiting significantly better tolerability. The encouraging results regarding tolerability and CD4+ T-cell responses for the Z-1018 candidate reflect the company's commitment to developing effective vaccines that leverage its innovative Toll-like Receptor Immune Modulation Platform technology. Additionally, the company's strong revenue generation from its CpG 1018 product and HEPLISAV-B indicates a solid financial foundation that supports its continued growth and investment in novel vaccine development.
Bears say
Dynavax Technologies Corp faces significant risks regarding its clinical development pipeline, as future candidates may fail to achieve critical efficacy endpoints or exhibit concerning safety profiles, potentially hindering regulatory approval and commercialization efforts. Furthermore, the company may struggle to effectively market its proprietary candidates due to challenging market conditions, increasing competition, or internal operational issues, which could diminish revenue potential. Additionally, uncertainties surrounding partnerships for its candidates could jeopardize commercial launches if terms are not favorable, further complicating Dynavax's financial outlook.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares